(Q38249954)

1 September 2017

1 reference

title

Overcoming multidrug resistance with nanomedicines (English)

1 reference

1 September 2017

main subject

multiple drug resistance

1 reference

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Assaf Ganoth

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Keren Cohen Merimi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

16 September 2014

1 reference

Expert Opinion on Drug Delivery

1 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

223-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25224685%20AND%20SRC:MED&resulttype=core&format=json

Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Paul Ehrlich's magic bullet concept: 100 years of progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Nanocarriers as an emerging platform for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Cancer nanotechnology: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Cell biological mechanisms of multidrug resistance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

ABC Transporters: From Microorganisms to Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Mammalian ABC transporters in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

P-glycoprotein: from genomics to mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

New light on multidrug binding by an ATP-binding-cassette transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Substrate recognition and transport by multidrug resistance protein 1 (ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Role of the MRP1/ABCC1 multidrug transporter protein in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Mammalian multidrug-resistance proteins (MRPs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Role of transmembrane segment 5 and extracellular loop 3 in the homodimerization of human ABCC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Advances in Homology Protein Structure Modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

A multidrug resistance transporter from human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Molecular pharmacology of ABCG2 and its role in chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Homology modeling of breast cancer resistance protein (ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Long-circulating polymeric nanovectors for tumor-selective gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Doxil®--the first FDA-approved nano-drug: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Protein nanoparticles as drug carriers in clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Recent advances with liposomes as pharmaceutical carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Drug delivery systems: entering the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Nanoparticles for imaging, sensing, and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Special delivery: targeted therapy with small RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

A daunting task: manipulating leukocyte function with RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Polysaccharides as building blocks for nanotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Thermo- and pH-responsive polymers in drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Fluoxetine and reversal of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Rationally designed nanovehicles to overcome cancer chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Omics-based nanomedicine: the future of personalized oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Precision nanomedicine in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

Precision medicine--delivering the goods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

RNAi-based nanomedicines for targeted personalized therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920

VMD: visual molecular dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.960920